30 results about "Postoperative inflammation" patented technology

An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).

Methods of tissue passivation are described herein for use in preserving normal tissue architecture, reducing post-surgical inflammation, and reducing or preventing the development of pathogenic collagen bundles and adhesions following surgical procedures. Passivated tissues prepared in accordance with these methods are useful in a variety of therapies including, e.g., cardiac bypass surgery, hemodialysis, etc.

The invention discloses a preparation method of polysialic acid-hyaluronic acid composite gel, an obtained product and an application. The preparation method comprises steps as follows: in an alkaline aqueous solution environment, polysialic acid is linked with a crosslinking agent, and activated polysialic acid is obtained; the activated polysialic acid is added to a hyaluronic acid solution, so that the polysialic acid is grafted on the hyaluronic acid in an acid environment, and the product is obtained. The reaction process is controllable, few side reactions exist, the obtained product has excellent biocompatibility of the hyaluronic acid and non-immunogenicity of the polysialic acid, can be applied to embedded slow-release of polypeptide or protein drugs and can also applied to coating of crosslinked hyaluronic acid gel particles for injection, the postoperative inflammatory reaction is reduced, skin redness and swelling are relieved, pain of users is relieved, besides, the product stability can be improved, the degradation time can be prolonged, and the half-life period can be prolonged.

The invention discloses a medical nanofiber reinforced hydrophilic composite material as well as a preparation method and application thereof. The composite material is prepared from a hydrophilic basis material and nano staple fibers, wherein the nano staple fibers are maintained in crystal morphology and are uniformly dispersed in the hydrophilic basis material; the mass percent of the nano staple fibers in the composite material is 1 to 30 percent; the nano staple fibers have the diameters of 200nm to 800nm and the lengths of 10mu m to 100mu m; according to the preparation method of the medical nanofiber reinforced composite material, which is provided by the invention, the technological design is peculiar; the nano staple fibers are uniformly dispersed in the basis material by utilizing the solubility difference of the basis material and the nano staple fibers; the multicellular spongy composite material is obtained by adopting a freeze drying method; the composite material keeps the respective advantages of two materials; defects are complementary; the composite material which is excellent in mechanical performance, good in biocompatibility and good in biodegradability is obtained, and the medical nanofiber reinforced hydrophilic composite material is moderate in degradation cycle, cannot cause a postoperative inflammation and the postoperative risk of adhesion, is more suitable for clinical demand.

The invention discloses a flushing fluid for an external eye operation and a preparation method of the flushing fluid, and belongs to the technical field of surgical flushing fluids. The flushing fluid contains the following components: NaCl, KCl, CaCl2H2O, MgCl2.6H2O, C2H3NaO2.3H2O, C6H5Na3O7.2H2O, cocamidopropyl betaine, digitalin, Esculin, an amnion extracting solution, trehalose and hyaluronicacid. Through combined application of all the components, grease in an operation area, tissue debris generated in an operation and the like can be cleaned more easily, the cleanliness of the operation area is improved, the number of flora of conjunctival sacs is reduced, tissue repair can be promoted, postoperative inflammatory response is relieved, and discomforts such as eye edema, hyperemia and dryness are relieved. Meanwhile, the solutions are less irritating, have no toxic or side effect, are low-cost, and are suitable for wide clinical application.

Methods of treating a subject after ocular surgery are disclosed. The methods include administering to an eye of a subject in need thereof a composition comprising at least one corticosteroid or an ophthalmically acceptable salt thereof in an ophthalmically acceptable vehicle that can provide a sustained release of the at least one corticosteroid or an ophthalmically acceptable salt thereof. Advantageously, the composition does not result in a statistically significant elevation in intraocular pressure in a statistically significant number of subject eyes when administered twice daily over a period of two weeks.

The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.

The invention discloses an implantation method of a deep flexible brain electrode combined with drug delivery. The implantation method comprises a flexible brain electrode pretreatment step and a flexible brain electrode implantation step; the flexible brain electrode pretreatment step specifically comprises the steps of forming a cured protein protection layer on the surface of the flexible brainelectrode, wherein the cured protein protection layer comprises a drug to be delivered. According to the implantation method, the cured protein protection layer is formed on the surface of the flexible brain electrode, so that the Young modulus of the flexible brain electrode can be increased to a degree sufficient to be implanted into the brain, and high biocompatibility and minimally invasive property are achieved. The protein protection layer contains a certain concentration of to-be-delivered drug, so that intraoperative infection and postoperative inflammatory response can be effectivelyinhibited. The implantation operation of the flexible brain electrode is convenient and simple, and the implantation success rate is high.

The invention relates to an ophthalmic pharmaceutical preparation for treating conjunctivitis, scleritis and eye postoperative inflammations, in particular to a sustained-release bromfenac sodium ophthalmic preparation. The sustained-release bromfenac sodium ophthalmic preparation provided by the invention is prepared from bromfenac sodium, carthamin yellow, sodium hyaluronate and a pharmacologically acceptable carrier. The sustained-release bromfenac sodium ophthalmic preparation provided by the invention has the advantages of good intraocular penetrability, high intraocular bioavailability,high penetration, high targeting effect, small toxic and side effects and the like, and is suitable for treating inflammatory eye diseases and used for treating conjunctivitis, scleritis and eye postoperative infection.

The invention discloses a traditional Chinese medicine decoction for auxiliary treatment of appendicitis; the traditional Chinese medicine decoction is prepared from the following raw material medicines in parts by weight: 30-40 parts of honeysuckle, 10-14 parts of liquorice, 10-14 parts of dandelion, 8-10 parts of safflower, 6-8 parts of radix aucklandiae, 13-17 parts of dried tangerine or orange peel and 3-7 parts of fructus cinnamomi. The invention also provides a preparation method of the decoction. The decoction has the advantages of promoting blood circulation to remove blood stasis, improving postoperative intestinal blood circulation, and promoting dissipation of inflammation, can reduce the patient postoperative inflammation, bleeding and other symptoms, reduces the pain of patients, and accelerates the postoperative recovery of the patients.

The invention belongs to a drug release coating of a degradable drug-coated stent of coronary stents in the medicinal material field. The drug release coating is composed of drug for inhibiting thrombosis and tissue hyperplasia and a polymer carrier. The drug can be rapamycin, tacrolimus or paclitaxel, wherein, the polymer carrier in the drug release coating is poly ortho ester (POE). The invention is the drug release coating of the degradable drug-coated stent which is especially applied to coronary interventional operations. With the poly ortho ester used as the carrier, the stent can lead to the long-acting release of the drug coated on the surface of the stent, improve the stability of the drug, achieve more ideal effects of the drug release, prolong the physical activity of the drug and reduce the toxic and side effects of the drug, thereby preventing the occurrence of postoperative inflammation effectively.

The invention relates to the field of medical implant materials and instrument surface modification in the ophthalmology department, in particular to a foldable intraocular lens with a concentric ring pattern, drug sustained release function and a surface modified by a degradable drug sustained-release coating, and a preparation method of the foldable intraocular lens. The degradable drug sustained-release coating with the concentric ring pattern is formed by spin-coating a sustained-release drug composition on the surface of the intraocular lens, and the sustained-release drug composition comprises a degradable polymer, a drug and an organic solvent. The spin-coating technology is applied, the drug sustained-release coating has the special concentric ring pattern with the thin center and the thick periphery, the influence on refraction, stability and foldability of the intraocular lens is small, and the drug sustained-release coating is not prone to falling off and can be stably attached to the surface of the intraocular lens, through drug reasonable selection, the intraocular lens can be used for effectively preventing various common complications after cataract phacoemulsification surgery, such as posterior capsular opacity, intraocular inflammation and other postoperative inflammatory reactions, and the surgery effect is guaranteed.

The invention discloses application of HAP1 in screening neuroinflammation treatment drugs, and belongs to the technical field of biological medicines. According to the invention, an HAP1 wild type mouse is selected as a control group, an HAP1 heterozygote mouse is selected as an experimental group, neuropathologic acute pain is constructed, and postoperative inflammatory responses of the two groups of mice are respectively detected. Results show that by reducing the expression of the HAP1, the inflammatory response can be obviously reduced, the activation level of glial cells is reduced, and the release of inflammatory factors is inhibited; and finally, the effect of controlling neuroinflammation is achieved. The discovery can provide a new molecular target for pain research.

The invention provides a Beta-tricalcium phosphate bearing tetracycline. The tetracycline is absorbed on the surface of the Beta-tricalcium phosphate, and the mass ratio of the tetracycline and the Beta-tricalcium phosphate is (0.001-0.1):1. The invention also provides a preparation method of the Beta-tricalcium phosphate bearing tetracycline, comprising the following steps: dissolving teline powder in a tetracycline solution formed in deionized water, uniformly mixing the calcined Beta-tricalcium phosphate powder and the tetracycline solution, extracting a solid component in the mixed solution, finally drying the solid component, and preparing and obtaining Beta-tricalcium phosphate powder bearing tetracycline on the surface. The Beta-tricalcium phosphate prepared by the method has better tetracycline bearing capacity, is used for repairing and replacing osseous tissues and also effectively eliminates postoperative inflammation.

The invention relates to a split-type patella jaw contractor, which comprises a cambered jaw the shape of which corresponds to that of a split-type patella jaw, wherein the cambered jaw is provided with a left cambered jaw and a right cambered jaw which correspond to each other; the left cambered jaw is provided with two jaws; the right cambered jaw is provided with a jaw; a vertical mounting plate is fixed on the upper end of each cambered jaw; a rectangular rod is vertically fixed on the mounting plate of the left cambered jaw; a strip-shaped surface of the rectangular rod is provided with continuous teeth to form a toothed rack; a hole and a sleeve for the rectangular rod to pass through are arranged on the mounting plate of the right cambered jaw; and a spring knob for braking and loosening the rectangular rod is arranged on the sleeve. The spit-type patella jaw contractor has the advantages of small volume, convenient operation, avoidance of bending limitation after healing of the knee joint, avoidance of postoperative inflammation and pain, short surgical time, simultaneously capability of performing pressurization between broken ends well and tightly combining the patella jaw and the patella, and short healing time.

The invention discloses a bionic drug-loaded nanoparticle for a specific targeted pulsed electric field ablation postoperative inflammatory region and a preparation method. The bionic drug-loaded nanoparticle comprises a drug-loaded liposome and a neutrophile granulocyte membrane coated on the surface of the drug-loaded liposome. The preparation method comprises the following steps: obtaining a neutrophile granulocyte membrane from activated neutrophile granulocytes through an osmotic pressure gradient method, then mixing the neutrophile granulocyte membrane with a drug-loaded liposome, and treating the obtained mixture through a nano extruder to obtain the neutrophile granulocyte membrane drug-loaded nanoparticles. The neutrophile granulocyte membrane targeting drug-loading nanoparticles with targeting ability are prepared by creatively wrapping the neutrophile granulocyte membrane on the surface of the drug-loading liposome by utilizing the characteristics that neutrophile granulocyte has high expelling ability on an inflammation site and can gather on the inflammation site. Based on the principle that neutrophile granulocytes are naturally collected to an inflammatory site after pulsed electric field ablation, a focus in an inflammatory state is targeted, and drugs are released, so that the focus is precisely targeted and treated.